Introduction

PTEN hamartoma tumor syndromes genetic testing is addressed by this guideline.

Procedures addressed

The inclusion of any procedure code in this table does not imply that the code is under management or requires prior authorization. Refer to the specific Health Plan's procedure code list for management requirements.

<table>
<thead>
<tr>
<th>Procedures addressed by this guideline</th>
<th>Procedure codes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Genomic Unity PTEN Analysis</td>
<td>0235U</td>
</tr>
<tr>
<td>PTEN Deletion/Duplication Analysis</td>
<td>81323</td>
</tr>
<tr>
<td>PTEN Known Familial Mutation Analysis</td>
<td>81322</td>
</tr>
<tr>
<td>PTEN Sequencing</td>
<td>81321</td>
</tr>
</tbody>
</table>

What is PTEN hamartoma tumor syndrome?

Definition

PTEN hamartoma tumor syndrome (PHTS) is used to describe the group of conditions caused by PTEN mutations that include hamartomatous growths: Cowden syndrome (CS), Bannayan-Riley-Ruvalcaba syndrome (BRRS), Proteus syndrome and Proteus-like syndrome, and autism spectrum disorder with macrocephaly.¹

Prevalence

The prevalence is unknown. The prevalence of CS was previously estimated to be 1 in 200,000 individuals, although this is likely low due to underdiagnosis.¹

Symptoms

Historically, these conditions have been considered clinically distinct but share an underlying genetic etiology, and show some overlap in families.¹

• **Cowden syndrome** (CS) is characterized by an increased risk for benign and malignant tumors of the breast, endometrium, and thyroid (non-medullary).¹ ²
Other common features include macrocephaly and growths on the skin or mucous membranes (mucocutaneous lesions). The lifetime risk for breast cancer is 25-50% with an average age at diagnosis of 38-46 years. However, a 2012 publication by Tan et al. reports that this lifetime risk may be as high as 85%, particularly in individuals with PTEN promoter mutations.

The lifetime risk for thyroid cancer can range from 10% to as high as 35%. If it occurs, thyroid cancer is usually follicular. It is rarely papillary and is never medullary. Benign thyroid growths are also found in up to 75% of individuals with CS. “However, the high frequency of thyroid disease in the general population means that when taken on their own, thyroid neoplasms have a low predictive value for identifying mutations carriers.”

Endometrial cancer has an estimated 5-10% lifetime risk, although this is not well-defined. Tan et al. reports a lifetime risk of up to 28%.

The gastrointestinal polyp risk (often colonic) in patients with CS may be 80% or higher and the lifetime risk for colorectal cancer is estimated to be 9%.

Early onset colorectal cancer has been reported in 13% of patients with PTEN associated CS indicating earlier and more frequent colonoscopy is warranted in this population.

Additionally, an increased lifetime risk for kidney cancer (approximately 34%) and melanoma (about 5-6%) has been reported.

- **Lhermitte-Duclos disease** (LDD) is a rare, benign tumor of the cerebellum called dysplastic gangliocytoma that may present in childhood or adulthood. Most adult-onset LDD is caused by a PTEN mutation even when no other signs of CS are present.

- **Bannayan-Riley-Ruvalcaba syndrome** (BRRS) is a genetic disorder characterized by macrocephaly, multiple benign intestinal polyps (hamartomatous type), lipomas, colored spots on the tip of the penis (pigmented macules of the glans penis), and hemangiomas. Some people with BRRS have intellectual disability and/or birth defects. There may be an increased risk for several types of cancer, including breast, thyroid and endometrial.

- **Proteus and Proteus-like syndromes** are highly variable conditions characterized by overgrowth of several different tissues usually in a patchy asymmetric pattern (mosaic) that is often present from birth but gets worse over time. Clinical signs and symptoms include connective tissue and epidermal nevi (hamartomatous growths), ovarian cystadenomas, parotid monomorphic adenomas, lipomas, capillary/venous/lymphatic malformations, and a characteristic facial dysmorphology.

- **Autism spectrum disorder with macrocephaly** (defined as >2.5 SDs above the age mean or ≥97th percentile) may be caused by a mutation in the PTEN gene.

- **Juvenile polyposis of infancy** may be caused by mutations in PTEN. In this condition, juvenile polyposis is diagnosed before six years of age. “Often the
gastrointestinal manifestations of bleeding, diarrhea, and protein-losing enteropathy are severe. External stigmata may mimic BRRS.\textsuperscript{1}

**Cause**

Pathogenic mutations in the PTEN gene cause PHTS.

- Up to 80\% of people with a clinical diagnosis of CS have a PTEN mutation in the coding region.\textsuperscript{1} Ten percent of individuals with CS have a PTEN mutation in the promoter region.\textsuperscript{1} The majority of CS cases are simplex.
- Approximately 10-50\% of individuals with CS have an affected parent.\textsuperscript{1} De novo PTEN pathogenic variants occur in 10\%-44\% of individuals with PHTS.
- Nearly all individuals with a PTEN mutation will develop symptoms (complete penetrance).\textsuperscript{1,2}
- Up to 71\% of individuals with a clinical diagnosis of BRRS have a PTEN mutation.\textsuperscript{1} Up to 50\% of individuals with Proteus-like syndrome and 20\% of individuals with Proteus syndrome have a PTEN mutation.\textsuperscript{1} An estimated 3-20\% of all individuals with ASD/macrocephaly have a PTEN mutation.\textsuperscript{1,7} The likelihood may be greater if other family members have signs and symptoms in the PHTS spectrum.

**Inheritance**

PTEN mutations are inherited in an autosomal dominant manner, meaning that a person only needs a mutation in one copy of the gene to be affected. A child of an affected person has a 50\% chance to inherit the mutation.

**Diagnosis**

The diagnosis of PHTS can be established with the identification of a pathogenic mutation in the PTEN gene. Clinical diagnostic criteria have been developed. A clinical diagnosis of PHTS is based on the major and minor criteria in the table below.\textsuperscript{2}

An operational diagnosis of CS is established if an individual meets any of the following criteria:

- Three or more major criteria* (one must include macrocephaly, Lhermitte-Duclos disease, or GI hamartomas); or
- Two major* and three minor** criteria

If an individual meets the clinical criteria noted above or has a PTEN pathogenic mutation, the family members would meet criteria for an operational diagnosis of CS if they meet one of the following criteria:

- Two major criteria* with or without minor criteria; or
- One major* and two minor criteria**; or
- Three minor** criteria
The major and minor criteria for a clinical diagnosis of PHTS are:²

<table>
<thead>
<tr>
<th>Major:*</th>
<th>Minor:**</th>
</tr>
</thead>
<tbody>
<tr>
<td>Breast cancer</td>
<td>Autism spectrum disorder</td>
</tr>
<tr>
<td>Endometrial cancer</td>
<td>Colon cancer</td>
</tr>
<tr>
<td>Follicular thyroid cancer</td>
<td>At least three esophageal glycogenic acanthoses</td>
</tr>
<tr>
<td>Three or more GI hamartomas (including ganglioneuromas but excluding hyperplastic polyps)</td>
<td>At least three lipomas</td>
</tr>
<tr>
<td>Adult Lhermitte-Duclos disease</td>
<td>Intellectual disability (IQ of 75 or less)</td>
</tr>
<tr>
<td>Macrocephaly (at least 97th percentile: 58cm in adult women and 60cm in adult men)</td>
<td>Renal cell carcinoma</td>
</tr>
<tr>
<td>Macular pigmentation of glans penis</td>
<td>Testicular lipomatosis</td>
</tr>
<tr>
<td>Mucocutaneous lesions:</td>
<td>Papillary or follicular variant of papillary thyroid cancer</td>
</tr>
<tr>
<td>• At least three trichilemmomas (at least one biopsy proved)</td>
<td>Thyroid structural lesions (e.g., adenoma, nodule(s), goiter)</td>
</tr>
<tr>
<td>• At least three acral keratoses</td>
<td>• Vascular anomalies (including multiple intracranial developmental venous anomalies)</td>
</tr>
<tr>
<td>• At least three mucocutaneous neuromas</td>
<td></td>
</tr>
<tr>
<td>• At least three oral papillomas that are biopsy proven or diagnosed by a dermatologist</td>
<td></td>
</tr>
</tbody>
</table>

Management

People with CS need heightened cancer surveillance starting at age 18 years. This may begin earlier if warranted: "For those with a family history of a particular cancer type at an early age screening may be initiated five to ten years prior to the youngest diagnosis in the family".¹² The exception is children should have a yearly thyroid ultrasound starting at age 7 years and skin check with physical examination.¹ Because of the overlap in clinical phenotypes, people with other PTEN-related conditions are advised to follow the same heightened cancer surveillance guidelines as for CS.⁸⁹

Survival

Given the phenotypic spectrum of PHTS and underdiagnosis, especially of individuals with non-classic phenotypes, the prognosis for individuals with PHTS is unknown. The increased risk for malignant tumors is the largest factor impacting survival.
Test information

Introduction

Testing for PHTS may include known familial mutation analysis, sequence analysis, and/or deletion/duplication analysis.

PTEN Known Familial Mutation Analysis

Once the familial mutation is identified, testing for that one mutation can be offered to at-risk relatives. Such testing is much less expensive than complete gene testing and the results are highly reliable.

PTEN Sequence Analysis

This testing evaluates each DNA nucleotide to identify mutations throughout the gene. Such testing will detect a mutation in about 80% of people with a clinical diagnosis of CS and 60% of people with a clinical diagnosis of BRRS.¹

- **Sequencing of the promoter region** will detect an additional 10% of PTEN mutations that cause CS.¹ NCCN recommended comprehensive testing, which should include full sequencing, gene deletion/duplication analysis, and promoter analysis of the PTEN gene.² As such, it is important to determine whether or not the selected laboratory includes PTEN promoter analysis in their testing.²

PTEN Deletion/Duplication Analysis

This testing is used in cases where a mutation is not found by sequencing. The likelihood of identifying a deletion or duplication in people with clinically diagnosed CS is unknown but expected to be relatively low.¹ About 11% of people with BRRS have large PTEN gene deletions.¹

Guidelines and evidence

Introduction

The following section includes relevant guidelines and evidence pertaining to PHTS testing.

American College of Medical Genetics and Genomics

The American College of Medical Genetics and Genomics (ACMG, 2013) issued consensus practice guidelines on the genetics evaluation of autism. They proposed an evaluation scheme with three tiers. The first tier included routine studies such as chromosome analysis and fragile X genetic testing. PTEN gene testing is recommended as a second tier test when the head circumference is greater than 2.5 SDs above the mean (if no diagnosis is made via first tier testing).¹⁰
National Comprehensive Cancer Network

Evidence-based guidelines (Category 2A) from the National Comprehensive Cancer Network (NCCN, 2021) support the use of PTEN genetic testing in those with clinical features or a family history. They recommended PTEN genetic testing in any of the following situations:²

- Family history of a known PTEN mutation [PTEN known familial mutation testing is appropriate]
- Individual with a personal history of Bannayan-Riley-Ruvalcaba syndrome (BRRS)
- Individual meeting clinical diagnostic criteria for CS/PHTS
- Individual not meeting clinical diagnostic criteria for CS/PHTS with a personal history of any of the following:
  - Adult-onset Lhermitte Duclos disease (cerebellar dysplastic gangliocytoma)
  - Autism spectrum disorder and macrocephaly (greater than or equal to 97th percentile)
  - Two or more biopsy proven trichilemmomas
  - Macrocephaly and at least one other major*** criteria
  - Three major*** criteria without macrocephaly
  - One major*** and three or more minor**** criteria
  - Four or more minor**** criteria
- At-risk relative of someone clinically diagnosed with Cowden syndrome or BRRS (who has not had genetic testing), when the at-risk relative has at least one major*** or two minor**** criteria. Ideally, the at-risk person is a first-degree relative (parent, sibling, child) of someone clinically diagnosed, but testing more distant relatives is acceptable if closer relatives are not available or willing to have testing.

The major and minor criteria to determine appropriateness of genetic testing are:
### Selected Relevant Publication

An expert-authored review of the PTEN hamartoma syndromes stated:

1. "Sequence analysis of PTEN is performed first and followed by gene-targeted deletion/duplication analysis if no pathogenic variant is found. If a pathogenic variant is not identified with deletion/duplication analysis, perform sequence analysis of the PTEN promoter region for variants that decrease PTEN gene expression."

2. “The most serious consequences of PHTS relate to the increased risk of cancers including breast, thyroid, endometrial, and to a lesser extent, renal. In this regard, the most important aspect of management of any individual with a PTEN pathogenic variant is increased cancer surveillance to detect any tumors at the earliest, most treatable stages.”
Criteria

Introduction

Requests for PHTS testing are reviewed using the following criteria.

PTEN Known Familial Mutation Analysis

• Genetic Counseling:
  o Pre and post-test genetic counseling by an appropriate provider (as deemed by the Health Plan policy), AND

• Previous Testing:
  o No previous genetic testing that would detect the familial mutation, AND

• Diagnostic and Predisposition Testing:
  o Known deleterious family mutation in PTEN identified in 1\textsuperscript{st}, 2\textsuperscript{nd}, or 3\textsuperscript{rd} degree biologic relative(s), AND

• Rendering laboratory is a qualified provider of service per the Health Plan policy.

PTEN Sequencing with Promoter Analysis

• Genetic Counseling:
  o Pre and post-test genetic counseling by an appropriate provider (as deemed by the Health Plan policy), AND

• Previous Testing:
  o No previous sequencing of PTEN, AND

• Diagnostic Testing for Symptomatic Individuals
  o Personal history of ANY of the following:
    ▪ Bannayan Riley-Ruvalcaba syndrome; or
    ▪ Adult Lhermitte-Duclos disease (LDD); or
    ▪ Autism spectrum disorder and macrocephaly; or
    ▪ At least two biopsy-proven trichilemmomas; or
    ▪ At least two major criteria** (one must be macrocephaly); or
    ▪ Three major criteria** without macrocephaly; or
    ▪ One major** and at least three minor criteria***; or
    ▪ Four or more minor criteria***, OR

• Predisposition testing for Presymptomatic/Asymptomatic Individuals:
At-risk person with a family history of:

- A relative (includes first-degree relative or more distant relatives if the first-degree relative is unavailable or unwilling to be tested) with a clinical diagnosis of Cowden syndrome or BRR (no previous genetic testing); and
- One major** OR two minor criteria*** in the at-risk person, AND

- Rendering laboratory is a qualified provider of service per the Health Plan policy.

### PTEN Deletion/Duplication Analysis:

- Genetic Counseling:
  - Pre and post-test genetic counseling by an appropriate provider (as deemed by the Health Plan policy), AND
- Previous Testing:
  - Sequence analysis of PTEN has been performed and resulted negative, and
  - No previous deletion/duplication testing, AND
- Rendering laboratory is a qualified provider of service per the Health Plan policy.

### Criteria for testing purposes are:

<table>
<thead>
<tr>
<th><strong>Major:</strong></th>
<th><strong>Minor:</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Breast cancer</td>
<td>Autism spectrum disorder</td>
</tr>
<tr>
<td>Endometrial cancer</td>
<td>Colon cancer</td>
</tr>
<tr>
<td>Follicular thyroid cancer</td>
<td>≥ 3 esophageal glycogenic acanthoses</td>
</tr>
<tr>
<td>Multiple GI hamartomas or ganglioneuromas</td>
<td>Lipomas</td>
</tr>
<tr>
<td>Macrocephaly (at least 97th percentile: 58cm in adult women and 60cm in adult men)</td>
<td>Intellectual disability (IQ≤75)</td>
</tr>
<tr>
<td>Macular pigmentation of glans penis</td>
<td>Papillary or follicular variant of papillary thyroid cancer</td>
</tr>
<tr>
<td>Mucocutaneous lesions: one biopsy-proven trichilemmoma, multiple palmoplantar keratoses, multifocal or extensive oral mucosal papillomatosis, multiple cutaneous facial papules (often verrucous)</td>
<td>Thyroid structural lesions (e.g., adenoma, nodule(s), goiter)</td>
</tr>
<tr>
<td></td>
<td>Renal cell carcinoma</td>
</tr>
<tr>
<td></td>
<td>Single GI hamartoma or ganglioneuroma</td>
</tr>
<tr>
<td></td>
<td>Testicular lipomatosis</td>
</tr>
<tr>
<td></td>
<td>Vascular anomalies (including multiple intracranial developmental venous anomalies)</td>
</tr>
</tbody>
</table>
References

Introduction

These references are cited in this guideline.


